Inogen, Inc. (NASDAQ:INGN) to Post Q1 2024 Earnings of ($0.85) Per Share, William Blair Forecasts

Inogen, Inc. (NASDAQ:INGNFree Report) – Equities researchers at William Blair raised their Q1 2024 earnings estimates for shares of Inogen in a report issued on Thursday, February 29th. William Blair analyst M. Kaczor now forecasts that the medical technology company will post earnings per share of ($0.85) for the quarter, up from their previous forecast of ($0.88). William Blair has a “Outperform” rating on the stock. The consensus estimate for Inogen’s current full-year earnings is ($2.61) per share. William Blair also issued estimates for Inogen’s Q2 2024 earnings at ($0.70) EPS, Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($2.63) EPS, Q1 2025 earnings at ($0.49) EPS, Q2 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($1.35) EPS.

Separately, JPMorgan Chase & Co. dropped their price target on shares of Inogen from $8.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Inogen currently has a consensus rating of “Hold” and an average target price of $13.67.

Read Our Latest Research Report on INGN

Inogen Trading Down 4.9 %

INGN stock opened at $6.68 on Monday. Inogen has a 52 week low of $4.13 and a 52 week high of $15.48. The company has a market capitalization of $155.71 million, a price-to-earnings ratio of -1.51 and a beta of 1.03. The firm’s 50-day moving average is $6.91 and its two-hundred day moving average is $5.97.

Institutional Trading of Inogen

A number of hedge funds and other institutional investors have recently made changes to their positions in INGN. Advisor Group Holdings Inc. raised its holdings in shares of Inogen by 3,054.2% in the 1st quarter. Advisor Group Holdings Inc. now owns 3,722 shares of the medical technology company’s stock worth $119,000 after purchasing an additional 3,604 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Inogen by 1.0% in the 1st quarter. Bank of New York Mellon Corp now owns 181,133 shares of the medical technology company’s stock worth $5,871,000 after purchasing an additional 1,836 shares in the last quarter. US Bancorp DE raised its holdings in shares of Inogen by 273.0% in the 1st quarter. US Bancorp DE now owns 884 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 647 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Inogen by 66.5% in the 1st quarter. MetLife Investment Management LLC now owns 11,211 shares of the medical technology company’s stock worth $363,000 after purchasing an additional 4,479 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Inogen by 4.7% in the 1st quarter. Rhumbline Advisers now owns 54,415 shares of the medical technology company’s stock worth $1,764,000 after purchasing an additional 2,421 shares in the last quarter. 93.15% of the stock is currently owned by institutional investors.

About Inogen

(Get Free Report)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Articles

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.